{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T11:40:04Z","timestamp":1790422804457,"version":"4.1.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-025-04285-9","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T05:54:27Z","timestamp":1774936467000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Allogeneic CD56\u2009+\u2009cell infusion as a bridge to hematopoietic stem cell transplantation in relapsed\/refractory acute myeloid leukemia: a phase I clinical trial"],"prefix":"10.1007","volume":"75","author":[{"given":"Amin Shahbaz","family":"Ghasabeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirhossein","family":"Izadpanah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Bakhtiyaridovvombaygi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehrshad","family":"Seresht-Ahmadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahar","family":"Parkhideh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamide Rahmani","family":"Seraji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdollah","family":"Sabri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Somayeh","family":"Yazdanparast","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abbas","family":"Hajifathali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Gharehbaghian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3698-4342","authenticated-orcid":false,"given":"Elham","family":"Roshandel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,31]]},"reference":[{"issue":"1","key":"4285_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-019-0774-x","volume":"12","author":"C Lai","year":"2019","unstructured":"Lai C, Doucette K, Norsworthy K (2019) Recent drug approvals for acute myeloid leukemia. J Hematol Oncol 12(1):100","journal-title":"J Hematol Oncol"},{"issue":"2","key":"4285_CR2","doi-asserted-by":"publisher","first-page":"143","DOI":"10.5966\/sctm.2012-0109","volume":"2","author":"A Pandolfi","year":"2013","unstructured":"Pandolfi A, Barreyro L, Steidl U (2013) Concise review: preleukemic stem cells: molecular biology and clinical implications of the precursors to leukemia stem cells. Stem Cells Transl Med 2(2):143\u2013150","journal-title":"Stem Cells Transl Med"},{"issue":"5","key":"4285_CR3","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.tips.2024.03.005","volume":"45","author":"M Forsberg","year":"2024","unstructured":"Forsberg M, Konopleva M (2024) AML treatment: conventional chemotherapy and emerging novel agents. Trends Pharmacol Sci 45(5):430\u2013448","journal-title":"Trends Pharmacol Sci"},{"key":"4285_CR4","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1182\/blood-2023-185132","volume":"142","author":"T Ho","year":"2023","unstructured":"Ho T, Gor J, Murray G, Bouligny I, Maher K (2023) Impact of recent advancements in relapsed\/refractory acute myeloid leukemia on overall survival in clinical practice. Blood 142:1474","journal-title":"Blood"},{"issue":"5","key":"4285_CR5","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1002\/ajh.27625","volume":"100","author":"S Shimony","year":"2025","unstructured":"Shimony S, Stahl M, Stone RM (2025) Acute Myeloid Leukemia: 2025 update on diagnosis, risk-stratification, and management. Am J Hematol 100(5):860\u2013891","journal-title":"Am J Hematol"},{"key":"4285_CR6","unstructured":"SEER Cancer Stat Facts: Acute Myeloid Leukemia. National Cancer Institute. Bethesda, MD,. accessed November 7, 2025."},{"issue":"8","key":"4285_CR7","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.3324\/haematol.2018.208587","volume":"104","author":"B Ball","year":"2019","unstructured":"Ball B, Stein EM (2019) Which are the most promising targets for minimal residual disease-directed therapy in acute myeloid leukemia prior to allogeneic stem cell transplant? Haematologica 104(8):1521\u20131531","journal-title":"Haematologica"},{"issue":"1","key":"4285_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-017-0505-0","volume":"10","author":"FS Lichtenegger","year":"2017","unstructured":"Lichtenegger FS, Krupka C, Haubner S, K\u00f6hnke T, Subklewe M (2017) Recent developments in immunotherapy of acute myeloid leukemia. J Hematol Oncol 10(1):142","journal-title":"J Hematol Oncol"},{"issue":"2","key":"4285_CR9","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/nri3365","volume":"13","author":"H Spits","year":"2013","unstructured":"Spits H, Artis D, Colonna M, Diefenbach A, Di Santo JP, Eberl G et al (2013) Innate lymphoid cells\u2013a proposal for uniform nomenclature. Nat Rev Immunol 13(2):145\u2013149","journal-title":"Nat Rev Immunol"},{"issue":"10","key":"4285_CR10","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1080\/10428194.2019.1581935","volume":"60","author":"M Tsirogianni","year":"2019","unstructured":"Tsirogianni M, Grigoriou E, Kapsimalli V, Dagla K, Stamouli M, Gkirkas K et al (2019) Natural killer cell cytotoxicity is a predictor of outcome for patients with high risk myelodysplastic syndrome and oligoblastic acute myeloid leukemia treated with azacytidine. Leuk Lymphoma 60(10):2457\u20132463","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"4285_CR11","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1046\/j.1365-2141.2002.03495.x","volume":"117","author":"MW Lowdell","year":"2002","unstructured":"Lowdell MW, Craston R, Samuel D, Wood ME, O\u2019Neill E, Saha V et al (2002) Evidence that continued remission in patients treated for acute leukaemia is dependent upon autologous natural killer cells. Br J Haematol 117(4):821\u2013827","journal-title":"Br J Haematol"},{"issue":"2","key":"4285_CR12","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1046\/j.1365-2141.2002.03277.x","volume":"116","author":"GF Torelli","year":"2002","unstructured":"Torelli GF, Guarini A, Palmieri G, Breccia M, Vitale A, Santoni A et al (2002) Expansion of cytotoxic effectors with lytic activity against autologous blasts from acute myeloid leukaemia patients in complete haematological remission. Br J Haematol 116(2):299\u2013307","journal-title":"Br J Haematol"},{"key":"4285_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115718","volume":"168","author":"M Bakhtiyaridovvombaygi","year":"2023","unstructured":"Bakhtiyaridovvombaygi M, Yazdanparast S, Mikanik F, Izadpanah A, Parkhideh S, Shahbaz Ghasabeh A et al (2023) Cytokine-induced memory-like NK cells: emerging strategy for AML immunotherapy. Biomed Pharmacother 168:115718","journal-title":"Biomed Pharmacother"},{"issue":"12","key":"4285_CR14","doi-asserted-by":"publisher","first-page":"2849","DOI":"10.1007\/s00262-022-03217-1","volume":"71","author":"S Rahmani","year":"2022","unstructured":"Rahmani S, Yazdanpanah N, Rezaei N (2022) Natural killer cells and acute myeloid leukemia: promises and challenges. Cancer Immunol Immunother 71(12):2849\u20132867","journal-title":"Cancer Immunol Immunother"},{"key":"4285_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1112059","volume":"14","author":"SZ D\u2019Silva","year":"2023","unstructured":"D\u2019Silva SZ, Singh M, Pinto AS (2023) Nk cell defects: implication in acute myeloid leukemia. Front Immunol 14:1112059","journal-title":"Front Immunol"},{"issue":"8","key":"4285_CR16","doi-asserted-by":"publisher","first-page":"3051","DOI":"10.1182\/blood-2004-07-2974","volume":"105","author":"JS Miller","year":"2005","unstructured":"Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, Fautsch SK et al (2005) Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 105(8):3051\u20133057","journal-title":"Blood"},{"issue":"8","key":"4285_CR17","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1158\/1078-0432.CCR-17-3196","volume":"24","author":"AT Bj\u00f6rklund","year":"2018","unstructured":"Bj\u00f6rklund AT, Carlsten M, Sohlberg E, Liu LL, Clancy T, Karimi M et al (2018) Complete remission with reduction of high-risk clones following haploidentical NK-cell therapy against MDS and AML. Clin Cancer Res 24(8):1834\u20131844","journal-title":"Clin Cancer Res"},{"issue":"12","key":"4285_CR18","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H et al (2022) Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 140(12):1345\u20131377","journal-title":"Blood"},{"issue":"5","key":"4285_CR19","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1002\/ajh.27281","volume":"99","author":"SO Ciurea","year":"2024","unstructured":"Ciurea SO, Kongtim P, Srour S, Chen J, Soebbing D, Shpall E et al (2024) Results of a phase I trial with Haploidentical mbIL-21 ex vivo expanded NK cells for patients with multiply relapsed and refractory AML. Am J Hematol 99(5):890\u2013899","journal-title":"Am J Hematol"},{"issue":"24","key":"4285_CR20","doi-asserted-by":"publisher","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","volume":"21","author":"BD Cheson","year":"2003","unstructured":"Cheson BD, Bennett JM, Kopecky KJ, B\u00fcchner T, Willman CL, Estey EH et al (2003) Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 21(24):4642\u20134649","journal-title":"J Clin Oncol"},{"issue":"6","key":"4285_CR21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0123416","volume":"10","author":"PD Kottaridis","year":"2015","unstructured":"Kottaridis PD, North J, Tsirogianni M, Marden C, Samuel ER, Jide-Banwo S et al (2015) Two-stage priming of allogeneic natural killer cells for the treatment of patients with acute myeloid leukemia: a phase I trial. PLoS ONE 10(6):e0123416","journal-title":"PLoS ONE"},{"issue":"15","key":"4285_CR22","doi-asserted-by":"publisher","first-page":"4107","DOI":"10.1158\/1078-0432.CCR-16-2981","volume":"23","author":"H Dolstra","year":"2017","unstructured":"Dolstra H, Roeven MWH, Spanholtz J, Hangalapura BN, Tordoir M, Maas F et al (2017) Successful Transfer of Umbilical Cord Blood CD34(+) Hematopoietic Stem and Progenitor-derived NK Cells in Older Acute Myeloid Leukemia Patients. Clin Cancer Res 23(15):4107\u20134118","journal-title":"Clin Cancer Res"},{"issue":"10","key":"4285_CR23","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1016\/j.jcyt.2017.07.008","volume":"19","author":"M Boyiadzis","year":"2017","unstructured":"Boyiadzis M, Agha M, Redner RL, Sehgal A, Im A, Hou JZ et al (2017) Phase 1 clinical trial of adoptive immunotherapy using \u201coff-the-shelf\u201d activated natural killer cells in patients with refractory and relapsed acute myeloid leukemia. Cytotherapy 19(10):1225\u20131232","journal-title":"Cytotherapy"},{"issue":"2","key":"4285_CR24","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1038\/s41375-022-01789-6","volume":"37","author":"K Li","year":"2023","unstructured":"Li K, Du Y, Cai Y, Liu W, Lv Y, Huang B et al (2023) Single-cell analysis reveals the chemotherapy-induced cellular reprogramming and novel therapeutic targets in relapsed\/refractory acute myeloid leukemia. Leukemia 37(2):308\u2013325","journal-title":"Leukemia"},{"issue":"3","key":"4285_CR25","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1182\/blood-2014-10-551911","volume":"126","author":"F Thol","year":"2015","unstructured":"Thol F, Schlenk RF, Heuser M, Ganser A (2015) How i treat refractory and early relapsed acute myeloid leukemia. Blood 126(3):319\u2013327","journal-title":"Blood"},{"issue":"6","key":"4285_CR26","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1038\/leu.2017.23","volume":"31","author":"M Wattad","year":"2017","unstructured":"Wattad M, Weber D, D\u00f6hner K, Krauter J, Gaidzik VI, Paschka P et al (2017) Impact of salvage regimens on response and overall survival in acute myeloid leukemia with induction failure. Leukemia 31(6):1306\u20131313","journal-title":"Leukemia"},{"issue":"1","key":"4285_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00996-x","volume":"13","author":"J Xu","year":"2020","unstructured":"Xu J, Niu T (2020) Natural killer cell-based immunotherapy for acute myeloid leukemia. J Hematol Oncol 13(1):167","journal-title":"J Hematol Oncol"},{"issue":"8","key":"4285_CR28","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1016\/j.bbmt.2018.03.019","volume":"24","author":"TA Fehniger","year":"2018","unstructured":"Fehniger TA, Miller JS, Stuart RK, Cooley S, Salhotra A, Curtsinger J et al (2018) A phase 1 trial of CNDO-109-activated natural killer cells in patients with high-risk acute myeloid leukemia. Biol Blood Marrow Transplant 24(8):1581\u20131589","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"4285_CR29","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1186\/s12885-023-11610-x","volume":"23","author":"M Ahmadvand","year":"2023","unstructured":"Ahmadvand M, Barough MS, Barkhordar M, Faridfar A, Ghaderi A, Jalaeikhoo H et al (2023) Phase I non-randomized clinical trial of allogeneic natural killer cells infusion in acute myeloid leukemia patients. BMC Cancer 23(1):1090","journal-title":"BMC Cancer"},{"key":"4285_CR30","doi-asserted-by":"crossref","unstructured":"Otegbeye F, Cooper B, Caimi P, Zamborsky K, Reese-Koc J, Hillian A, et al. A Phase I Study to Determine the Maximum Tolerated Dose of ex Vivo Expanded Natural Killer Cells Derived from Unrelated, HLA-Disparate Adult Donors. Transplant Cell Ther. 2022;28(5):250.e1-.e8.","DOI":"10.1016\/j.jtct.2022.02.008"},{"issue":"9","key":"4285_CR31","doi-asserted-by":"publisher","first-page":"2539","DOI":"10.1007\/s00432-021-03821-1","volume":"148","author":"R M\u00fchleck","year":"2022","unstructured":"M\u00fchleck R, Scholl S, Hilgendorf I, Schrenk K, Hammersen J, Frietsch JJ et al (2022) Outcome of patients with relapsed or refractory acute myeloid leukemia treated with Mito-FLAG salvage chemotherapy. J Cancer Res Clin Oncol 148(9):2539\u20132548","journal-title":"J Cancer Res Clin Oncol"},{"issue":"11","key":"4285_CR32","first-page":"3543","volume":"109","author":"A Bataller","year":"2024","unstructured":"Bataller A, Kantarjian H, Bazinet A, Kadia T, Daver N, DiNardo CD et al (2024) Outcomes and genetic dynamics of acute myeloid leukemia at first relapse. Haematologica 109(11):3543","journal-title":"Haematologica"},{"issue":"7","key":"4285_CR33","doi-asserted-by":"publisher","first-page":"e611","DOI":"10.1016\/j.clml.2021.02.007","volume":"21","author":"ME Tenold","year":"2021","unstructured":"Tenold ME, Moskoff BN, Krishnan R, Rosenberg AS, Hoeg RT, Abedi M et al (2021) Retrospective analysis of adult patients with relapsed\/refractory acute myeloid leukemia treated with FLAG at a comprehensive cancer center. Clin Lymphoma Myeloma Leuk 21(7):e611\u2013e618","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"4285_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1005031","volume":"13","author":"MU Mushtaq","year":"2022","unstructured":"Mushtaq MU, Shahzad M, Shah AY, Chaudhary SG, Zafar MU, Anwar I et al (2022) Impact of natural killer cells on outcomes after allogeneic hematopoietic stem cell transplantation: a systematic review and meta-analysis. Front Immunol 13:1005031","journal-title":"Front Immunol"},{"issue":"11","key":"4285_CR35","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1182\/blood.2021013972","volume":"139","author":"JJ Bednarski","year":"2022","unstructured":"Bednarski JJ, Zimmerman C, Berrien-Elliott MM, Foltz JA, Becker-Hapak M, Neal CC et al (2022) Donor memory-like NK cells persist and induce remissions in pediatric patients with relapsed AML after transplant. Blood 139(11):1670\u20131683","journal-title":"Blood"},{"issue":"5","key":"4285_CR36","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/j.bbmt.2014.01.031","volume":"20","author":"I Choi","year":"2014","unstructured":"Choi I, Yoon SR, Park SY, Kim H, Jung SJ, Jang YJ et al (2014) Donor-derived natural killer cells infused after human leukocyte antigen-haploidentical hematopoietic cell transplantation: a dose-escalation study. Biol Blood Marrow Transplant 20(5):696\u2013704","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"4285_CR37","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/s41375-021-01349-4","volume":"36","author":"SO Ciurea","year":"2022","unstructured":"Ciurea SO, Kongtim P, Soebbing D, Trikha P, Behbehani G, Rondon G et al (2022) Decrease post-transplant relapse using donor-derived expanded NK-cells. Leukemia 36(1):155\u2013164","journal-title":"Leukemia"},{"key":"4285_CR38","volume":"15","author":"AM Abbasi","year":"2021","unstructured":"Abbasi AM, Shaikh U, Ali N, Haider MN (2021) Fludarabine-based salvage therapy for refractory\/relapsed acute leukemias: a single center experience. Leuk Res Rep 15:100235","journal-title":"Leuk Res Rep"},{"key":"4285_CR39","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13071842","author":"S An\u017eej Doma","year":"2024","unstructured":"An\u017eej Doma S, Sever M, Jako\u0161 G, Podgornik H (2024) FLAG\/FLAG-Ida regimen in secondary and relapsed\/refractory acute myeloid leukemia-even in the era of new treatment modalities still a significant player. J Clin Med. https:\/\/doi.org\/10.3390\/jcm13071842","journal-title":"J Clin Med"},{"key":"4285_CR40","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.canlet.2018.02.033","volume":"422","author":"M Vela","year":"2018","unstructured":"Vela M, Corral D, Carrasco P, Fern\u00e1ndez L, Valent\u00edn J, Gonz\u00e1lez B et al (2018) Haploidentical IL-15\/41BBL activated and expanded natural killer cell infusion therapy after salvage chemotherapy in children with relapsed and refractory leukemia. Cancer Lett 422:107\u2013117","journal-title":"Cancer Lett"},{"issue":"9","key":"4285_CR41","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1002\/eji.201948375","volume":"50","author":"XY Zhao","year":"2020","unstructured":"Zhao XY, Jiang Q, Jiang H, Hu LJ, Zhao T, Yu XX et al (2020) Expanded clinical-grade membrane-bound IL-21\/4-1BBL NK cell products exhibit activity against acute myeloid leukemia in vivo. Eur J Immunol 50(9):1374\u20131385","journal-title":"Eur J Immunol"},{"issue":"6","key":"4285_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101580","volume":"5","author":"Y Wang","year":"2024","unstructured":"Wang Y, Huang B, Liang T, Jiang L, Wu M, Liu X et al (2024) Venetoclax acts as an immunometabolic modulator to potentiate adoptive NK cell immunotherapy against leukemia. Cell Rep Med 5(6):101580","journal-title":"Cell Rep Med"},{"issue":"1","key":"4285_CR43","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.70169","volume":"29","author":"A Eckstrom","year":"2025","unstructured":"Eckstrom A, Tyagi A, Mahmood S, Wong L, Valamehr B, Rao A et al (2025) FT538, iPSC-derived NK cells, enhance AML cell killing when combined with chemotherapy. J Cell Mol Med 29(1):e70169","journal-title":"J Cell Mol Med"},{"issue":"1","key":"4285_CR44","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41420-025-02678-4","volume":"11","author":"D Kegyes","year":"2025","unstructured":"Kegyes D, Tat A, Vizitiu AS, Vazar-Tripon D, Ilie R, Tigu AB et al (2025) Comprehensive view on chemotherapy-free management of acute myeloid leukemia by using venetoclax in combination with targeted and\/or immune therapies. Cell Death Discov 11(1):379","journal-title":"Cell Death Discov"},{"key":"4285_CR45","doi-asserted-by":"publisher","DOI":"10.1177\/09636897231198178","volume":"32","author":"U Kulkarni","year":"2023","unstructured":"Kulkarni U, Arunachalam AK, Palani HK, Nair RR, Balasundaram N, Venkatraman A et al (2023) Haploidentical natural killer cell therapy as an adjunct to stem cell transplantation for treatment of refractory acute myeloid leukemia. Cell Transplant 32:9636897231198178","journal-title":"Cell Transplant"},{"key":"4285_CR46","doi-asserted-by":"crossref","unstructured":"Hong J, Min S, Park J, Fielder C, Hu Q, Kim S, et al. Therapeutic role of NK cells in treatment of myeloid malignancies using hypomethylating agents. Cancer Research. 2025;85(8_Supplement_1):891-.","DOI":"10.1158\/1538-7445.AM2025-891"},{"key":"4285_CR47","doi-asserted-by":"publisher","first-page":"977","DOI":"10.3389\/fimmu.2018.00977","volume":"9","author":"A Le Roy","year":"2018","unstructured":"Le Roy A, Pr\u00e9bet T, Castellano R, Goubard A, Riccardi F, Fauriat C et al (2018) Immunomodulatory Drugs Exert Anti-Leukemia Effects in Acute Myeloid Leukemia by Direct and Immunostimulatory Activities. Front Immunol 9:977","journal-title":"Front Immunol"},{"issue":"2","key":"4285_CR48","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1111\/trf.16790","volume":"62","author":"E Rubio-Azpeitia","year":"2022","unstructured":"Rubio-Azpeitia E, P\u00e9rez-Corral AM, Dorado-Herrero N, Monsalvo S, P\u00e9rez-Balsera G, Fern\u00e1ndez-Santos ME et al (2022) Clinical grade production of IL-15 stimulated NK cells for early infusion in adult AML patients undergoing haploidentical stem cell transplantation with post-transplant cyclophosphamide. Transfusion 62(2):374\u2013385","journal-title":"Transfusion"},{"key":"4285_CR49","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-008959","author":"AW Matson","year":"2024","unstructured":"Matson AW, Hullsiek R, Dixon KJ, Wang S, Lindstedt AJ, Friess RR et al (2024) Enhanced IL-15-mediated NK cell activation and proliferation by an ADAM17 function-blocking antibody involves CD16A, CD137, and accessory cells. J Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2024-008959","journal-title":"J Immunother Cancer"},{"key":"4285_CR50","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-169773","volume-title":"Higher-Dose Donor Derived Ex Vivo Expanded Natural Killer Cell Infusion Prior to Haploidentical Stem Cell Transplantation on Acute Myeloid Leukemia: Efficacy and Safety","author":"W Wang","year":"2022","unstructured":"Wang W, Liang Y, Song Y, Huang H, Wu B (2022) Higher-Dose Donor Derived Ex Vivo Expanded Natural Killer Cell Infusion Prior to Haploidentical Stem Cell Transplantation on Acute Myeloid Leukemia: Efficacy and Safety. American Society of Hematology Washington, DC"},{"key":"4285_CR51","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.859177","volume":"13","author":"M Tarannum","year":"2022","unstructured":"Tarannum M, Romee R, Shapiro RM (2022) Innovative strategies to improve the clinical application of NK cell-based immunotherapy. Front Immunol 13:859177","journal-title":"Front Immunol"},{"issue":"3","key":"4285_CR52","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/s41573-019-0052-1","volume":"19","author":"N Shimasaki","year":"2020","unstructured":"Shimasaki N, Jain A, Campana D (2020) NK cells for cancer immunotherapy. Nat Rev Drug Discov 19(3):200\u2013218","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"4285_CR53","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.jcyt.2016.12.006","volume":"19","author":"SR Jaiswal","year":"2017","unstructured":"Jaiswal SR, Zaman S, Nedunchezhian M, Chakrabarti A, Bhakuni P, Ahmed M et al (2017) CD56-enriched donor cell infusion after post-transplantation cyclophosphamide for haploidentical transplantation of advanced myeloid malignancies is associated with prompt reconstitution of mature natural killer cells and regulatory T cells with reduced incidence of acute graft versus host disease: a pilot study. Cytotherapy 19(4):531\u2013542","journal-title":"Cytotherapy"},{"issue":"9","key":"4285_CR54","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.humimm.2021.06.001","volume":"82","author":"XY Min","year":"2021","unstructured":"Min XY, Liu CF, Cao B, Zhang T, Yang X, Ma N et al (2021) Human CD3(+)CD56(+)NKT-like cells express a range of complement receptors and C3 activation has negative effects on these cell activity and effector function. Hum Immunol 82(9):625\u2013633","journal-title":"Hum Immunol"},{"issue":"10","key":"4285_CR55","doi-asserted-by":"publisher","first-page":"916","DOI":"10.4161\/cbt.25938","volume":"14","author":"W Guo","year":"2013","unstructured":"Guo W, Xing C, Dong A, Lin X, Lin Y, Zhu B et al (2013) Numbers and cytotoxicities of CD3+CD56+ t lymphocytes in peripheral blood of patients with acute myeloid leukemia and acute lymphocytic leukemia. Cancer Biol Ther 14(10):916\u2013921","journal-title":"Cancer Biol Ther"},{"issue":"10","key":"4285_CR56","doi-asserted-by":"publisher","first-page":"2923","DOI":"10.1182\/blood.V97.10.2923","volume":"97","author":"J Baker","year":"2001","unstructured":"Baker J, Verneris MR, Ito M, Shizuru JA, Negrin RS (2001) Expansion of cytolytic CD8(+) natural killer T cells with limited capacity for graft-versus-host disease induction due to interferon gamma production. Blood 97(10):2923\u20132931","journal-title":"Blood"},{"issue":"8","key":"4285_CR57","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1038\/ni1487","volume":"8","author":"ND Huntington","year":"2007","unstructured":"Huntington ND, Puthalakath H, Gunn P, Naik E, Michalak EM, Smyth MJ et al (2007) Interleukin 15-mediated survival of natural killer cells is determined by interactions among Bim, Noxa and Mcl-1. Nat Immunol 8(8):856\u2013863","journal-title":"Nat Immunol"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04285-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-025-04285-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04285-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T07:03:25Z","timestamp":1774940605000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-025-04285-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,31]]},"references-count":57,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["4285"],"URL":"https:\/\/doi.org\/10.1007\/s00262-025-04285-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7593855\/v1","asserted-by":"object"}]},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,31]]},"assertion":[{"value":"11 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"All patients and donors provided written informed consent in accordance with the principles outlined in the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}],"article-number":"124"}}